Baichuan
Enterprises and developers seeking Chinese-language large language models and AI solutions, particularly in the healthcare sector.
Overview
Baichuan AI (百川智能) is a Chinese artificial intelligence company headquartered in Beijing, founded in April 2023 by Wang Xiaochuan, the founder and former CEO of Sogou. The company develops large language models and AI assistants, with a focus on Chinese and multilingual capabilities. It is considered one of China's "AI Tiger" companies. Baichuan has raised significant funding from major investors including Tencent, Alibaba Group, Shunwei Capital, and Xiaomi, and was valued at $2.8 billion in a July 2024 funding round. In March 2025, the company announced a restructuring to focus on applying AI to healthcare.
Funding: Seed capital of $50 million; $300 million round in October 2023; $691 million round in July 2024 valuing the company at $2.8 billion. Total funding reported at approximately $1.04 billion.
What it does
Baichuan develops and releases large language models, including the open-source Baichuan1 and Baichuan2, and the later Baichuan3 and Baichuan4. The models are designed to handle long context windows, with Baichuan2 capable of processing around 350,000 Chinese characters. The company also offers a commercial API platform for its models, with per-token pricing. More recently, Baichuan has shifted focus toward AI applications in healthcare, including a medical AI model (Baichuan-M3) for clinical consultation.
Key features
- Open-source large language models (Baichuan1, Baichuan2)
- Large context window support (up to ~350,000 Chinese characters)
- Commercial API access with per-token pricing
- Models with over one trillion parameters (Baichuan3)
- AI assistant powered by upgraded LLM (Baichuan4)
- Medical AI for clinical consultation (Baichuan-M3)
- Private deployment solutions for enterprises
Use cases
- Academic research using open-source language models
- Building Chinese-language chatbots and AI assistants
- Processing and understanding long Chinese text documents
- Enterprise private deployment of LLMs
- Medical consultation and clinical decision support
Pricing
Per-token API pricing, with rates ranging from ¥0.00098/1K tokens (Baichuan4-Air) to ¥0.1/1K tokens (Baichuan4). Pricing details are available on the platform site (platform.baichuan-ai.com/prices).
Pricing is gathered from the company's public pages and may change. Check the vendor's site before buying.
Pros and cons
Strengths
- Strong backing from major Chinese tech investors (Tencent, Alibaba, Xiaomi)
- Proven track record of releasing multiple model generations
- Capability to handle very long Chinese text contexts
- Open-source models available for research use
- Focus on high-value healthcare applications
Limitations
- Pricing not published on the main website; requires contacting sales or using the platform
- Primarily focused on Chinese language and market, with limited international presence
- Company restructuring in 2025 may create uncertainty about product roadmap
- No free tier or self-serve option mentioned on the main website
What sets it apart
- One of China's six 'AI Tiger' companies
- Founded by Sogou's former CEO Wang Xiaochuan
- Models specifically optimized for Chinese language and long-context processing
- Pivot to healthcare AI applications
Frequently asked questions
Who founded Baichuan AI?
Baichuan was founded in April 2023 by Wang Xiaochuan, who previously founded Sogou and served as its CEO.
Where is Baichuan AI headquartered?
Baichuan AI is headquartered in Beijing, China.
What are Baichuan's main products?
Baichuan has released several large language models: Baichuan1 (June 2023), Baichuan2 (November 2023), Baichuan3 (January 2024), and Baichuan4 (May 2024). It also offers a commercial API platform and has developed a medical AI model called Baichuan-M3.
How is Baichuan AI funded?
Baichuan secured $50 million in seed capital at founding, a $300 million round in October 2023 (with investors including Tencent, Alibaba, Shunwei Capital, and Xiaomi), and a $691 million round in July 2024 that valued the company at $2.8 billion.
What is Baichuan's current strategic focus?
In March 2025, Baichuan announced a restructuring to focus on applying AI to healthcare.
Sources
This profile was compiled from the company's own pages and public web research.
Last researched August 11, 2026.
Manage this listing
Own this company? Update your listing information.